Safe­ty con­cerns lead FDA to re­ject Ake­bi­a's kid­ney drug

The FDA on Wednes­day re­ject­ed Ake­bia Ther­a­peu­tics’ vadadu­s­tat, once a fron­trun­ner to treat ane­mia due to chron­ic kid­ney dis­ease, due to safe­ty con­cerns.

In is­su­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER